Takeda New Frontier Science (NFS) aims to build relationships with academics and entrepreneurs developing disruptive ideas to improve patients' lives.

There have been multiple attempts by healthcare companies to develop early-stage ideas from academia and entrepreneurs into the next blockbuster product but the challenges to success remain severe.

Into this (mine)field is stepping Japan-based drugs company Takeda Pharmaceuticals, which could launch its early-stage development initiative as early as next month.

Takeda New Frontier Science (NFS) aims to build relationships with academics and entrepreneurs developing disruptive ideas to improve patients’ lives.

Juan Harrison has moved from the drugs company’s US-based corporate venturing unit, Takeda Ventures (TVI), to head up NFS. In a Global Corporate Venturing webinar hosted by US-based academia organisation National Council of Entrepreneurial Tech Transfer (NCET2), Harrison said the aim of NFS was to "position Takeda as a most-favoured innovation partner" so it could gain insights into new technologies and access data.

For this to happen, he said the "relationship to innovator is key" and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?